Evaluating Surface Area Reduction Using MolecuLight Imaging Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-10

Study Completion Date

2017-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

12-week single-blind, prospective, randomized, controlled, pilot clinical trial assessing The MolecuLight i:X Imaging Device in chronic wounds. This device guides clinicians to inspect, sample, debride or further evaluate areas within or around a wound where potentially harmful bacteria appear under violet light illumination resulting in better overall care and accelerated surface area reduction compared to current standard care. The study aims to determine if this device aids in the healing of chronic wounds by reduction in size of wound compared to current standard of care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds

NCT03091361

Wounds and Injuries

COMPLETED

Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds

NCT02682069

Wounds

COMPLETED NA

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

NCT04207099

Non Healing Diabetic Foot Ulcer

UNKNOWN

The Effectiveness of a Mechanical Debridement Instrument in Reducing Bioburden in Chronic Wounds

NCT04342767

Acute Wounds Chronic Wounds

COMPLETED

Moleculight i:X™ in Wound Healing

NCT03270904

Ulcer Foot

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, 12-week, single-blinded, randomized, controlled clinical trial has been designed with two primary objectives needed to inform more comprehensive studies at a later date. We propose to evaluate the following two primary outcomes: (1) the ability of the MolecuLight i:X Imaging Device to predict non healing wounds and wounds at risk or infection (control arm) and (2) whether utilization of the MolecuLight i:X Imaging Device in guiding clinicians to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present (treatment arm) increases wound healing rates relative to standard care (control arm) for the treatment of chronic wounds.

Both arms will receive standard procedures associated with wound care (e.g., sampling, debridement, preventative care, infection control, etc.) according to best practice guidelines. Patients will be randomly assigned to either the control or treatment arm and be followed as per the study protocol every time their wound is cared for over a 12-week period. The effectiveness of the MolecuLight i:X Imaging Device will be assessed with evaluation of wound surface area reduction rate and infection rates (incidence of infection and time to eradicate infection) compared to standard care.

All subjects randomized will be evaluated for 12 weeks from the date of enrollment and treatment initiation. Subjects who may have wound closure within the 12-week study period will continue to have scheduled study evaluation visits up to the end of week 12.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Wound Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This will be a single blinded randomised trial where the control group will be receiving a standard wound care whereas the treatment group would also be receiving standard wound care but under the guidance of the imaging device.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Caregivers Investigators

Investigator will be blinded to study Clinical staff that will evaluate wounds at baseline, 2, 4, 6, 8, 10 and 12 weeks after date of randomisation and therapy initiation will be blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

This arm group (control) will receive standard wound care of chronic wounds

Group Type OTHER

Wound care

Intervention Type PROCEDURE

Standard wound care of chronic wounds e.g. sampling, debridement, infection control

Treatment

The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present

Group Type OTHER

MolecuLight i:X™ Imaging Device

Intervention Type DEVICE

Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MolecuLight i:X™ Imaging Device

Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.

Intervention Type DEVICE

Wound care

Standard wound care of chronic wounds e.g. sampling, debridement, infection control

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age ≥ 18 years
2. having a chronic wound that is not a diabetic foot ulcer
3. presence of the wound for ≥ 6 weeks and ≤ 2 years.
4. wound size surface area ≥ 2 cm2 and ≤ 50 cm2.
5. Willingness to comply with prescribed wound care regimen

Exclusion Criteria

1. candidate for surgery in the next 12 weeks
2. a wound with necrotic tissue unable to tolerate debridement
3. uncontrolled diabetics (defined as HbA1c of \>85.5mmol/mol)
4. presence of a diabetic foot ulcer
5. currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)
6. women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control
7. participation in another investigative drug or device trial currently or within the last 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes